OVH supports your development with the best web solutions: hosting, domain name, dedicated server, CDN, Cloud, Big Data, ...
Location: Ireland
Total raised: $29M
Investors 2
| Date | Name | Website |
| - | Valiance | valiance-a... |
| - | NeoMed Man... | neomed.net... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.03.2016 | Series B | $29M | - |
Mentions in press and media 5
| Date | Title | Description |
| 10.03.2016 | 4Tech brings in $29M Series B for its transcatheter device for Tricuspid Regurgitation | The financing round was led by Valiance and RMM, with participation from NeoMed Management and a group of Business Angels with a strong track record in Aortic and Mitral Structural Heart Disease. Photo: Screenshot via 4Tech Promoted Clinica... |
| 09.03.2016 | 4Tech Completes $29 Million Series B Round of Financing | Funding will support further Clinical Evaluation and Market Access for 4Tech TriCinch™, a breakthrough technology for Transcatheter Valve Repair (TTVR). GALWAY, Ireland, March 9, 2016 — 4Tech Inc., a privately held pioneer in the transcath... |
| 09.03.2016 | 4Tech Completes $29 Million Series B Round of Financing | Funding will support further Clinical Evaluation and Market Access for 4Tech TriCinch™, a breakthrough technology for Transcatheter Tricuspid Valve Repair (TTVR) GALWAY, Ireland–(BUSINESS WIRE)–March 9, 2016– 4Tech Inc., a privately held pi... |
| 09.03.2016 | 4Tech Secures $29M in Series B Financing | 4Tech Inc., a developer of solutions for transcatheter treatment of Tricuspid Regurgitation (TR), secured $29m in series B financing. The round was led by Valiance and RMM, with participation from existing and new investors NeoMed Managemen... |
| - | 4Tech brings in $29M Series B for its transcatheter device for Tricuspid Regurgitation | Galway, Ireland-based 4Tech has raised $29 million in a Series B financing round, which will be used to gain European approval of its TriCinch device used to treat Tricuspid Regurgitation (TR). TR is a condition in which blood “backflows” i... |